Market Multiple Has Fallen Below Its 3 Year Average
For the first time since Liberation Day, the S&P 500’s multiple has fallen below its three-year average, a level that over the past several years, has typically been associated with a resumption of multiple expansion. One of the more surprising developments so far has been the strength of corporate earnings alongside continued stock selloffs. Notably, the prospect of increased capex spending, which was viewed positively last year, is no longer being received the same way. This shift may reflect growing shareholder concerns about how that spending will ultimately be funded.

The Dip In Technology Multiples Is Getting To Extreme Territory
The irony of AI is that the technology sector, which benefited so much last year, is now bearing the brunt of concerns about the potential decline of the software industry. Sector multiples have compressed rapidly, falling from 28x to 23x in just two months. This magnitude of compression is more typical of broader market corrections. For context, in 2022 multiples declined from 27x to 18x, and last April they compressed from 27x to 21x.
A Basket Of Companies Not Mentioning AI Is Showing Strong Performance
A basket of companies constructed, comprised of firms that did not mention the term “artificial intelligence” on their earnings calls, has delivered strong performance over the past week (which should come as no surprise). From an industry perspective, the basket is far more diversified than one might initially expect. Notably, technology has no representation at all.
Source: Strategas
Chart reflects price changes, not total return. Because it does not include dividends or splits, it should not be used to benchmark performance of specific investments. Data provided by Refinitiv.
Sincerely,
Fortem Financial
(760) 206-8500
team@fortemfin.com
Latest News
US software stocks tumble sparks concerns that AI trade is reshaping markets
The software and services industry's recent plunge has ignited fears that the artificial intelligence boom may be reshaping markets in unexpected ways, raising questions about whether a rotation out of technology stocks signals trouble ahead for the AI trade.
Reuters
Novo Nordisk sues Hims after $49 weight-loss pill sparks FDA backlash
Novo Nordisk sued Hims and Hers Health on Monday over patent infringement after the U.S. telehealth firm launched, then cancelled, a $49 copy of Novo's weight-loss pill Wegovy following a swift backlash from U.S. authorities.
Reuters


